ICI 170809

Drug Profile

ICI 170809

Alternative Names: ZM 170809

Latest Information Update: 06 Sep 2000

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiarrhythmics; Antidepressants; Antiplatelets; Small molecules
  • Mechanism of Action Platelet aggregation inhibitors; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Ischaemic heart disorders; Major depressive disorder; Thrombosis

Most Recent Events

  • 06 Sep 2000 Discontinued-II for Depression in United Kingdom (Unknown route)
  • 06 Sep 2000 Discontinued-II for Thrombosis in United Kingdom (Unknown route)
  • 06 Sep 2000 Discontinued-II for Ischaemic heart disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top